Neoplasms
Conditions
Brief summary
The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.
Detailed description
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood) and determining the dose and dose schedule for the next phase of studies with SNS-595.
Interventions
DRUGSNS-595
Sponsors
Sunesis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must give written informed consent * 18 years of age * Advanced solid malignant tumors * Tumor can be measured and evaluated * Blood tests are within standard limits * Normal blood coagulation * ECOG Performance Status equal to 0 or 1
Exclusion criteria
* Pregnant or breastfeeding. * Women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards. * Heart attack, stroke/TIA or other blood clotting event (deep vein thrombosis or pulmonary embolus) within 6 months before the screen visit. * Requires kidney dialysis (hemodialysis or peritoneal). * Known bleeding disorder (ie, hemophilia, von Willebrand Disease, coagulopathy, etc.). * Received an investigational agent or prior chemotherapy or immunotherapy within 28 days before first dose of SNS-595 * Receiving therapeutic anticoagulation therapy (coumadin, heparin, etc.). * Currently receiving corticosteroids (inhaled steroids for breathing diseases are allowed) or seizure medications. * Any medical, psychological, or social condition that, in the opinion of the Principal Investigator, would contraindicate the patient's participation in the clinical trial due to safety and or compliance with study procedures.
Countries
United States
Outcome results
None listed